Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN

Biotechnology

Healthcare
$945.53 -0.90%

-$5.45 today

Market cap
$97.80B
Beta
0.24
P/E (TTM)
14.2
EPS (TTM)
$42.53
Dividend yield
0.60%
52W Low $506.38High $821.11

Volume 0.70M

Average 0.91M

REGN Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Regeneron Pharmaceuticals, Inc.NASDAQ: REGN

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit growth accelerates

Q2 FY2026 gross profit of $3.71B rose 18.1% year over year, ahead of the +8.4% change in trailing-twelve-month gross profit. Sequentially, it rose 26.5% from the prior quarter. Over 3 fiscal years it compounded at +5.4% a year.

Context

  • Gross profit amounted to 85.4% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +18.1% holds above the trailing-twelve-month pace of +8.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.71B+26.5% QoQ
Last fiscal yearDec 2025
$12.24B+0.1% YoY
LTMJun 2026
$13.18B+8.4% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.1%——
1 year+0.1%——
3-year CAGR+5.4%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
12.24B USD
Year-over-year change
+0.1%
4-year CAGR
-2.1%

Gross Profit vs competitors

How REGN compares with its peers on the latest reported figures

  • REGN's LTM Jun 2026 gross profit of $13.18B is the 5th highest of the 9 companies compared; the peer median is $15.49B.
  • Its year-over-year change of +8.4% is the 2nd highest of 8, against a peer median of -1.6%.
  • Gross profit amounts to 84.9% of revenue for REGN, versus a peer median of 78.0%.
REGN Competitors Peer median
Gross Profit for REGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AZNAstraZeneca PLCLTM Sep 2026$49.79B +4.0%+14.6%80.1%
NVSNovartis AGLTM Jun 2026$41.41B -1.6%+8.9%74.4%
AMGNAmgen Inc.LTM Jun 2026$27.7B +23.1%+9.3%72.7%
GILDGilead Sciences, Inc.LTM Jun 2026$24.24B +6.9%+2.4%79.6%
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026$13.18B +8.4%+5.4%84.9%
BIIBBiogen Inc.LTM Jun 2026$6.74B -7.1%-4.3%67.7%
GMABGenmab A/SLTM Jun 2026$3.84B —-38.3%93.0%
OCULOcular Therapeutix, Inc.LTM Mar 2026$45.4M -16.1%-1.2%87.2%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$5.83M -88.9%-4.0%76.5%
Peer median (excluding REGN) $15.49B-1.6%+0.6%78.0%

Competitors are the stored peer set for REGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue16.07B12.17B13.12B14.2B14.34B
Cost of Revenue2.72B1.71B2.24B1.97B2.1B
Gross Profit13.35B10.47B10.87B12.23B12.24B
Gross Margin83.1%86.0%82.9%86.1%85.4%
Research & Development2.62B3.06B3.99B5.23B5.85B
Selling, General & Admin1.82B2.12B2.54B2.95B2.7B
Operating Expenses4.4B5.08B6.52B8.24B8.66B
Depreciation & Amortization286.2M341.4M421M482.9M543.7M
EBITDA9.67B5.26B4.69B5.32B5.82B
EBITDA Margin60.2%43.2%35.8%37.4%40.6%
Operating Income8.95B5.39B4.35B3.99B3.58B
Operating Margin55.7%44.2%33.2%28.1%24.9%
Interest Income0160.1M495.9M711.4M716.8M
Interest Expense57.3M59.4M73M55.2M43.8M
Other Income / Expenses379M(526.8M)(149.3M)789.2M1.65B
Income Before Tax9.33B4.86B4.2B4.78B5.23B
Pre-Tax Margin58.0%39.9%32.0%33.7%36.5%
Income Tax Expense1.25B520.4M245.7M367.3M725.8M
Net Income8.08B4.34B3.95B4.41B4.5B
Net Margin50.2%35.6%30.1%31.1%31.4%
EPS (Basic)76.4040.5137.0540.9043.07
EPS (Diluted)71.9738.2234.7738.3441.48
Weighted Avg Shares105.7M107.1M106.7M107.9M104.6M
Weighted Avg Shares (Diluted)112.2M113.5M113.7M115.1M108.6M

Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN

Intrinsic Alpha fair value

Locked

Current Price

$945.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.